Saturday, June 13, 2026
🇺🇸 FDA

Drug profile · INN

ak112

ak112 is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 0
Pipeline programs 4
News articles 1
Drug details — ak112
Class
—
Route
—
Patents
0
Programs
4
Data quality
0.70
← All drugs Search patents Pipeline programs Drug news hub Event calendar

Quick answer

ak112 is an FDA-listed pharmaceutical active ingredient.

Key facts

INN ak112

Approval history

Authority Status Date
NMPA clinical trials —

Recent coverage

View all news
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
High impact Analysisnon-small cell lung cancerJun 6, 2026

Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?

FDA · non-small cell lung cancer · 5 min

While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.

Dr. Sarah Mitchell

Pipeline programs

Search pipeline
  1. AK112 Injection Phase 3 · Summit Therapeutics · Non-Squamous Non-small Cell Lung Cancer
  2. AK112 Phase 2 · Summit Therapeutics · Metastatic Colorectal Cancer
  3. AK112-210 Phase 2 · Akeso · Metastatic Pancreatic Ductal Adenocarcinoma
  4. Ivonescimab combined with TP Phase 2 · Chinese Academy of · Head and Neck Squamous Cell Carcinoma

Frequently asked questions

What is ak112?

ak112 is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.